Genelux Corporation

Healthcare

NASDAQ:GNLX · NASDAQ Global Market

Market Cap $107.21M Beta 0.55 P/E (TTM) -3.0

$2.97 +2.63%

+$0.08 today

52W Low $2.29High $8.54

Vol 0.10M · Avg 0.19M

EPS (TTM) -$0.98Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+7.04%

Period High

$8.24

Period Low

$2.30

Latest

$2.97

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Alpha Tau Medical Ltd.

NASDAQ:DRTS

$853.58M

Candel Therapeutics, Inc.

NASDAQ:CADL

$449.08M

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

$444.15M

Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

$391.08M

Silence Therapeutics plc

NASDAQ:SLN

$321.19M

Cellectis S.A.

NASDAQ:CLLS

$308.78M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

$293.31M

AC Immune S.A.

NASDAQ:ACIU

$242.73M

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

$114.01M

Mereo BioPharma Group plc

NASDAQ:MREO

$50.71M

What is the latest GNLX filing?

The latest filing shown is 4 dated Jun 4, 2026.

How many recent filings does GNLX have?

Intrinsic Alpha currently shows 20 recent filings for GNLX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.